Date | Price Target | Rating | Analyst |
---|---|---|---|
8/2/2024 | $9.00 → $3.00 | Neutral → Underweight | Piper Sandler |
7/10/2024 | $8.00 | Mkt Perform | Raymond James |
9/20/2023 | $9.00 → $16.00 | Hold → Buy | Jefferies |
6/16/2023 | Outperform → Market Perform | TD Cowen | |
7/29/2022 | Buy → Hold | Truist | |
7/29/2022 | $12.00 → $5.00 | Outperform → Sector Perform | RBC Capital Mkts |
7/28/2022 | Overweight → Neutral | JP Morgan | |
6/13/2022 | $12.00 | Overweight | JP Morgan |
Piper Sandler downgraded Bausch Health from Neutral to Underweight and set a new price target of $3.00 from $9.00 previously
Raymond James initiated coverage of Bausch Health with a rating of Mkt Perform and set a new price target of $8.00
Jefferies upgraded Bausch Health from Hold to Buy and set a new price target of $16.00 from $9.00 previously
SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)
SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)
SC 13G/A - Bausch Health Companies Inc. (0000885590) (Subject)
Truist Securities analyst Gregory Fraser maintains Bausch Health Companies (NYSE:BHC) with a Hold and lowers the price target from $8 to $7.
Bausch Health Companies Inc. (NYSE:BHC) is experiencing a sharp decline in its stock price Wednesday. The drop was triggered by a report suggesting the company is negotiating a potential prepackaged Chapter 11 bankruptcy with co-op creditor. The company later issued a statement, firmly denying any discussions related to bankruptcy or insolvency proceedings. What Happened: The initial report from Reorg indicates that Bausch Health might be in talks with its creditors about a potential prepackaged bankruptcy to address its balance sheet issues. The company emphasized that the article in question contained “unsubstantiated rumors” and clarified that it has not been involved in any talks w
S-8 - Bausch Health Companies Inc. (0000885590) (Filer)
10-Q - Bausch Health Companies Inc. (0000885590) (Filer)
8-K - Bausch Health Companies Inc. (0000885590) (Filer)
Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basisConsolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10%Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidanceLAVAL, QC / ACCESSWIRE / August 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2024 financial results and other key updates from the quarter."We continued our momentum in the second quarter, delivering our fifth
LAVAL, QC / ACCESSWIRE / July 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2024 financial results on Thursday, August 1, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Thursday, August 1, 2024Time:8:00 a.m. U.S. ESTWebcast:http://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in the live Q&A session, please
First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basisYear-over-year revenue growth in all segments on both a Reported and Organic1 BasisGAAP Net Loss Attributable to Bausch Health Companies Inc. of $64 MillionAdjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $665 Million, up 13%Xifaxan® Appeal Decision Represents a Significant Milestone related to Full Separation of Bausch + LombReaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidanceLAVAL, QC / ACCESSWIRE / May 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its first quarter 2024 financia
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
LAVAL, QC / ACCESSWIRE / September 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the approval by Health Canada of PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1%, a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older.1CABTREO is the first and only triple-combination topical treatment for acne approved by Health Canada with three mechanisms of action - an antibiotic, a retinoid and an antibacterial agent - to provide a safe and effective treatment.1"The approval of CABTREO shows the continuing commitment of Bausch Health to
Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basisConsolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10%Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidanceLAVAL, QC / ACCESSWIRE / August 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2024 financial results and other key updates from the quarter."We continued our momentum in the second quarter, delivering our fifth
LAVAL, QC / ACCESSWIRE / July 24, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") has become aware of a news article issued by Reorg® today, citing unnamed sources.The article contains unsubstantiated rumors, including that the Company is considering a bankruptcy or insolvency proceeding of any kind - it is not.We understand that Reorg® has subsequently issued an update to its original news article to clarify that the Company has not been involved in discussions with its creditors regarding bankruptcy proceedings.The Company's policy is not to provide further comment on speculation.About Bausch HealthBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversi
LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT).Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 years of experience in financial leadership roles with public and private companies across healthcare, high tech and services, primarily at General Electric, Hewlett Packard, Novartis and Purdue Pharma. Upon JJ's arrival, John Barresi, the Company's Interim Chief Financial Officer, will resume his role as SVP, Controller.Aimee Lenar joined the Company on July 15, 2024 as Executive Vice President, US Pharm
BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders (IFFGD) today announced they are joining forces to declare Tuesday, Dec. 5, Opioid-Induced Constipation (OIC) Awareness Day. OIC Awareness Day aims to bring awareness to an often-overlooked side effect of opioids. This day will help patients suffering from OIC by breaking down the stigma and silence surrounding this condition."OIC Awareness Day will help bridge the gap between healthcare providers (HCPs), patients, and caregivers by providing
Partnership Aims to Educate Hispanic Communities About the Signs, Symptoms, and Prevalence of Gum DiseaseCollaboration Launches During Hispanic Heritage Month With Activations Featuring Patient Ambassador Alex RodriguezLAVAL, QC / ACCESSWIRE / September 21, 2023 / In honor of Hispanic Heritage Month, Bausch Health Companies Inc. (NYSE:BHC),(TSX:BHC) and its oral health care business, OraPharma, today announced its collaboration with the League of United Latin American Citizens (LULAC) - the largest and oldest Hispanic organization in the United States - to foster a greater understanding of gum disease detection, and treatment within the Hispanic community.Gum disease, also known as periodont